Key Takeaways:
- Thermo Fisher delivered strong first-quarter results with revenue of $10.36 billion and adjusted EPS of $5.15, exceeding expectations despite macro uncertainties.
- The company has updated its 2025 guidance to reflect the impacts of tariffs and policy changes, with adjusted EPS now expected to be in the $21.76-$22.84 range.
- Management outlined comprehensive mitigation strategies, including supply chain adjustments, pricing actions, and $2 billion in additional U.S. manufacturing investments.
- Get accurate financial data on over 100,000 global stocks for free on TIKR >>>
Valued at a market capitalization of $151 billion, Thermo Fisher Scientific (TMO) operates as the world’s leading provider of analytical instruments, equipment, reagents, consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics.
It serves customers across pharmaceutical, biotech, academic, government, and industrial markets through its comprehensive portfolio of life sciences solutions.
TMO stock has demonstrated resilience amid unprecedented policy uncertainty. The company has proactively addressed potential tariff impacts and regulatory changes while maintaining strong operational execution.
TMO stock has tripled in the past decade. However, it has underperformed the broader markets in recent years.
Let’s explore why you might consider adding this large-cap healthcare stock to your equity portfolio today.
1. TMO Stock Benefits from Strong Q1 Execution
TMO stock reflects the company’s exceptional first-quarter performance that exceeded expectations across key financial metrics.
Revenue reached $10.36 billion with adjusted operating income of $2.27 billion, delivering an adjusted operating margin of 21.9%. Despite facing headwinds from fewer selling days and pandemic-related revenue runoff, it achieved organic revenue growth of 1%.
Performance across end markets demonstrated the resilience of Thermo Fisher’s diversified business model. The pharmaceutical and biotech segment, which accounts for over half of total revenue, delivered low single-digit growth, driven by strong performance in bioproduction and pharmaceutical services.
Industrial and applied markets demonstrated solid momentum, with strong growth in electron microscopy, while specialty diagnostics achieved 4% organic growth, driven by healthcare market channels and immunodiagnostics.
The company’s innovation pipeline continued delivering breakthrough products, including the Vulcan Automated Lab for semiconductor manufacturing and the next-generation Transcend chromatography platform.
These high-impact innovations strengthen Thermo Fisher’s competitive positioning and support long-term market share gains across key customer segments.
Check out TMO’s full analyst estimates and growth forecast (It’s free) >>>
2. Thermo Fisher Positioned for Policy Navigation
The TMO stock price incorporates management’s comprehensive assessment of tariff impacts and policy changes affecting the business.
It updated its full-year guidance to reflect an estimated $1 per share impact from macroeconomic changes, including $0.70 from China-related tariffs and $0.30 from changes in U.S. policy focus affecting academic and government customers.
Thermo Fisher’s mitigation strategy includes aggressive supply chain adjustments, appropriate pricing actions, and leveraging its extensive global manufacturing network.
Its scale advantages enable rapid production shifts across geographies, with twin factories and robust capabilities in every major market providing operational flexibility that smaller competitors cannot match.
Non-China-related tariffs are expected to have no net EPS impact in 2025, as the company implements offsetting measures, including supply chain adjustments, cost management, and pricing adjustments.
The temporary reduction in China tariff rates to 10% from previously announced 145% levels provides meaningful relief for TMO’s operations in China.
Find the best stocks to buy today with TIKR. (It’s free) >>>
3. TMO Stock Should Gain from Enhanced U.S. Manufacturing Investment Strategy
TMO stock benefits from a strategic decision to invest approximately $2 billion over four years in expanding U.S. manufacturing capabilities.
This investment addresses growing customer demand for domestic production capacity, positioning Thermo Fisher to capture reshoring opportunities across the pharmaceutical and biotech markets.
TMO’s pharma services business is experiencing significant demand for U.S.-based contract development and manufacturing capabilities, particularly in fill-finish operations and drug product manufacturing.
Customer interest in leveraging domestic capacity reflects industry trends toward supply chain diversification and potential tariff mitigation strategies.
Thermo Fisher’s status as the largest domestic player in every major global market creates unique competitive advantages for serving local customers.
Its trusted partner relationships and proven ability to enable customer success provide differentiated value propositions that support market share gains during periods of industry consolidation.
Valuation Setup for TMO Stock
Analysts tracking TMO stock expect its sales to rise from $42.87 billion in 2024 to $49.6 billion in fiscal 2027, an annual increase of 5%. Comparatively, adjusted earnings are forecast to expand from $21.86 per share to $27.68 per share in this period.
TMO stock currently trades at a forward price-to-earnings multiple of 18x, which is below its 10-year average multiple of 22x.
If the large-cap stock is priced at a multiple of 17x and reaches its projected $27.86 in normalized EPS, it will trade around $475/share in early 2027, indicating an upside potential of almost 20% from current levels.
Value stocks quicker with TIKR (It’s free, no card required) >>>
Average Analyst Price Target for TMO Stock
While Wall Street remains bullish on TMO stock, with a consensus price target of $560/share, analysts expect the stock to rise around 40% from current levels.
Notably, TMO stock currently has a high target price of $767 and a low target price of $450.
Of the 30 analysts tracking TMO stock, 24 recommend “Buys”, and six recommend “Hold.” There are no “Sell” recommendations for the stock in June 2025.
TIKR Takeaway for TMO Stock
TMO stock represents a compelling opportunity for investors seeking exposure to the essential life sciences tools market through a proven industry leader.
Its comprehensive mitigation strategies, global scale advantages, and trusted customer relationships provide defensive characteristics during periods of policy uncertainty, while maintaining upside potential from innovation and market expansion.
Trading at current valuations, TMO stock offers attractive risk-adjusted returns, supported by a consistent track record of execution, a strong balance sheet, and a proven capital deployment strategy.
Thermo Fisher’s ability to navigate challenging environments while continuing to invest in growth initiatives demonstrates the durability of its competitive advantages and long-term value creation potential for shareholders seeking exposure to the life sciences innovation ecosystem.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
